Patents Assigned to Lixte Biotechnology, Inc.
  • Patent number: 10668062
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure (I).
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 2, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Patent number: 10618908
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 10532050
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells
  • Patent number: 10434100
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 8, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Patent number: 10413541
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 17, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Salvatore Lecca, Manuel Mameli
  • Patent number: 10399993
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: September 3, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Francis Johnson
  • Patent number: 10364252
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 30, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Publication number: 20190046525
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 14, 2019
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20180370983
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: June 26, 2018
    Publication date: December 27, 2018
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. KOVACH, Francis JOHNSON
  • Patent number: 10149847
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: December 11, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Publication number: 20180244690
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 10023587
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: July 17, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S Kovach, Francis Johnson
  • Patent number: 9994584
    Abstract: The present invention provides a process for producing the compound having the structure: comprising (a) reacting a compound having the structure: with a compound having the structure: in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: June 12, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventors: Jason J. Piotrowski, Dumitru Ionescu
  • Patent number: 9988394
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 5, 2018
    Assignee: Lixte Biotechnology Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Publication number: 20170369503
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S KOVACH, Francis JOHNSON
  • Patent number: 9833450
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: December 5, 2017
    Assignees: LIXTE BIOTECHNOLOGY, INC., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: John S Kovach, Salvatore Lecca, Manuel Mameli
  • Publication number: 20170340628
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 30, 2017
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20170305925
    Abstract: The present invention provides a process for producing the compound having the structure: comprising (a) reacting a compound having the structure: with a compound having the structure: in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.
    Type: Application
    Filed: October 14, 2015
    Publication date: October 26, 2017
    Applicant: Lixte Biotechnology, Inc.
    Inventors: Jason J. Piotrowski, Dumitru Ionescu
  • Publication number: 20170259081
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 14, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • Publication number: 20170240558
    Abstract: Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 24, 2017
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Francis JOHNSON, Ramakrishna SAMUDRALA